✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- IBS and IBD are different conditions with different treatments — IBS (irritable bowel syndrome) is a functional disorder, IBD (inflammatory bowel disease, including Crohn’s and ulcerative colitis) is structural inflammation. Most products in this category target IBD.
- 5-ASA / mesalamines (Mesacol, Mesacol OD, Asacol) are first-line for mild-to-moderate ulcerative colitis and remission maintenance.
- Sulfasalazine (Salazar, Sazo) is the older 5-ASA prodrug — still useful in IBD with concurrent rheumatoid arthritis (dual indication).
- Antispasmodics (Colospa / mebeverine) are the core IBS symptom-control option for cramping and abdominal pain.
- Rifaximin (Rifagut) is gut-selective antibiotic for IBS-D and hepatic encephalopathy prevention.
- Below: 7 evidence-backed treatments across IBS and IBD, with mechanism, indication, and decision shortcut.
Best IBS & IBD Treatments in 2026: 7 Evidence-Backed Picks for Bowel Disease
“IBS or IBD?” is the question that drives treatment selection. They sound similar but are fundamentally different — IBS is a functional disorder of altered gut motility and visceral hypersensitivity without structural disease; IBD is autoimmune inflammation that damages the bowel wall. Misdiagnosis between the two is common and consequential — IBD treatments don’t help IBS, and IBS treatments don’t address IBD inflammation. This guide ranks the 7 most-used treatments across both conditions, with a clear emphasis on which condition each drug actually addresses.
Important — IBS is NOT the same as IBD. Persistent diarrhoea with weight loss, blood in stool, nocturnal symptoms, fever, or family history of bowel cancer needs proper diagnostic workup before assuming IBS. A clinician can order calprotectin, CRP, FBC, and (where indicated) colonoscopy to distinguish IBS from IBD, microscopic colitis, coeliac disease, and other organic causes. 5-ASAs and sulfasalazine are not appropriate for IBS — they treat the inflammation that doesn’t exist in functional bowel disorders.
How modern IBS / IBD treatment is structured
For IBS, the 2024 BSG and AGA updates emphasise stratifying by predominant symptom (IBS-D, IBS-C, IBS-M) and matching treatment: mebeverine and other antispasmodics for cramping; loperamide or rifaximin for IBS-D; soluble fibre, polyethylene glycol, or linaclotide for IBS-C; low-FODMAP dietary intervention; gut-directed CBT for refractory cases; tricyclic antidepressants at low dose for visceral pain modulation.
For IBD (ulcerative colitis or Crohn’s), treatment escalates by severity: 5-ASAs for mild-moderate ulcerative colitis; corticosteroids for acute flare; immunomodulators (azathioprine, methotrexate) and biologics (anti-TNF, vedolizumab, ustekinumab) for moderate-severe disease and steroid-dependent cases. The medications stocked here address the 5-ASA / sulfasalazine tier — the foundation of mild-to-moderate UC management and remission maintenance. Severe IBD requires specialist care that goes beyond what oral generics can provide.
1. Mesacol (Mesalamine 400 mg)
Class: 5-Aminosalicylate (5-ASA) · Manufacturer: Sun Pharma · View product · For IBD, not IBS
Mesalamine is the first-line oral 5-ASA for mild-to-moderate ulcerative colitis — both for inducing remission of acute flare and for long-term maintenance. Mechanism is local anti-inflammatory action at the colonic mucosa via inhibition of NF-κB and prostaglandin/leukotriene pathways. Mesacol uses a pH-dependent coating that releases mesalamine in the terminal ileum and colon. Standard dosing 800–4800 mg daily for active disease, 1200–2400 mg daily for maintenance.
Side effects: headache, nausea, paradoxical worsening of colitis (rare hypersensitivity-like reaction — distinct from disease flare), interstitial nephritis (annual creatinine and urinalysis recommended), pancreatitis, blood dyscrasias.
Pick for: mild-to-moderate ulcerative colitis flare, UC remission maintenance, mild Crohn’s colitis (less effective than in UC).
2. Mesacol OD (Mesalamine 1.2 g extended-release)
Class: 5-ASA (once-daily extended-release) · Manufacturer: Sun Pharma · View product · For IBD, not IBS
Mesacol OD is a once-daily, high-strength formulation of mesalamine that delivers the same active drug in a pH-dependent multi-matrix system designed for distal colon delivery. Once-daily dosing improves adherence vs the divided-dose 400 mg formulation — and adherence is the strongest predictor of remission maintenance in ulcerative colitis. Total daily dose 2.4–4.8 g.
Pick for: ulcerative colitis remission maintenance where adherence is the key constraint, distal/left-sided UC where colonic delivery matters.
3. Asacol (Mesalamine delayed-release)
Class: 5-ASA (delayed-release) · Manufacturer: Tillotts Pharma · View product · For IBD, not IBS
Asacol uses Eudragit-S coating that releases mesalamine at pH ≥7, targeting the terminal ileum and colon. Same active ingredient as Mesacol — different release mechanism. Useful when patients haven’t responded to pH-dependent or matrix-system delivery; some patients respond better to Eudragit-coated formulations and vice versa. The choice between Mesacol, Mesacol OD, and Asacol is largely about the colonic delivery mechanism best suited to the disease distribution.
Pick for: ulcerative colitis treatment failure on alternative mesalamine formulation, terminal ileal Crohn’s disease.
4. Salazar (Sulfasalazine 500 mg)
Class: Sulfa-prodrug 5-ASA · Manufacturer: WHO-GMP certified · View product · For IBD or rheumatoid arthritis
Sulfasalazine is the original 5-ASA — sulfapyridine + 5-ASA linked by an azo bond that’s cleaved by colonic bacteria. The 5-ASA portion provides the anti-inflammatory effect; the sulfapyridine accounts for most of the side effects. Still useful in two situations: (1) IBD (especially with concurrent rheumatoid arthritis where sulfasalazine has dual disease activity), (2) rheumatoid arthritis as a DMARD. Modern mesalamine preparations have largely displaced sulfasalazine in pure IBD therapy because of better tolerability.
Side effects: nausea, headache (high incidence early), reversible male infertility (oligospermia, reverses on discontinuation), photosensitivity, rash, blood dyscrasias, reversible elevation of liver enzymes, folate deficiency (folate supplementation often needed), orange-yellow discolouration of urine and skin (harmless).
Pick for: IBD with concurrent rheumatoid arthritis, alternative 5-ASA when mesalamine isn’t tolerated or affordable, rheumatoid arthritis as a DMARD.
5. Sazo (Sulfasalazine 500 mg)
Class: Sulfa-prodrug 5-ASA · Manufacturer: WHO-GMP certified · View product · For IBD or rheumatoid arthritis
Sazo is an alternative sulfasalazine brand — same molecule as Salazar, alternative manufacturer for cost-conscious continuous therapy. The 500 mg tablet supports the standard 2–4 g daily dosing for active IBD or RA. Folate supplementation (1 mg daily) is standard alongside sulfasalazine to offset its anti-folate effect.
Pick for: long-term sulfasalazine therapy when alternative manufacturer is preferred, RA as DMARD.
6. Colospa (Mebeverine 135 mg)
Class: Antispasmodic (musculotropic) · Manufacturer: Solvay · View product · For IBS, not IBD
Mebeverine is the most-prescribed antispasmodic for IBS in the UK and Europe. Acts directly on intestinal smooth muscle (musculotropic) without the antimuscarinic side-effect profile of older agents like hyoscine. Reduces cramping and abdominal pain associated with IBS without affecting normal gut motility or causing constipation. Standard dosing 135 mg three times daily 20 minutes before meals; once-daily extended-release formulations also available.
Side effects: very well tolerated. Rare allergic reactions (rash, urticaria), occasional dizziness or headache. Does not cause drowsiness or interfere with driving. Safer than older antispasmodics in older patients.
Pick for: IBS with cramping and abdominal pain (any IBS subtype), functional bowel disorders with smooth-muscle hyperactivity, chronic abdominal pain syndromes.
7. Rifagut (Rifaximin 200/400/550 mg)
Class: Gut-selective antibiotic (rifamycin) · Manufacturer: Sun Pharma · View product · For IBS-D, hepatic encephalopathy
Rifaximin is a near-non-absorbed gut-selective antibiotic — <0.4% systemic absorption means activity is confined to the gut lumen with minimal systemic toxicity. The TARGET 1, 2, and 3 trials established efficacy for IBS-D and small intestinal bacterial overgrowth (SIBO), with sustained symptom relief 6–10 weeks after a 14-day 550 mg three-times-daily course. Also primary indication for prevention of recurrent hepatic encephalopathy in cirrhotics.
Side effects: generally well tolerated due to minimal systemic absorption; nausea, abdominal pain, peripheral oedema. Avoids most class-effects of systemic antibiotics. Resistance is theoretically a concern but clinically rare due to its gut-selective profile.
Pick for: IBS-D (predominant diarrhoea), suspected SIBO, hepatic encephalopathy prophylaxis, traveller’s diarrhoea (alternative to ciprofloxacin in fluoroquinolone-resistant areas).
Comparison table: 7 IBS & IBD treatments at a glance
| Treatment | Class | For IBS or IBD | Best for | Key consideration |
|---|---|---|---|---|
| Mesacol | 5-ASA | IBD only | Mild-mod UC, maintenance | Annual renal monitoring |
| Mesacol OD | 5-ASA once-daily | IBD only | UC maintenance + adherence | High-strength formulation |
| Asacol | 5-ASA delayed-release | IBD only | UC, terminal ileal Crohn’s | Eudragit-S delivery |
| Salazar | Sulfa-prodrug 5-ASA | IBD or RA | IBD+RA dual indication | Folate supplementation |
| Sazo | Sulfa-prodrug 5-ASA | IBD or RA | Cost-conscious sulfasalazine | Same as Salazar |
| Colospa | Antispasmodic | IBS only | IBS cramping & pain | Very well tolerated |
| Rifagut | Gut-selective antibiotic | IBS-D, HE prophylaxis | IBS-D, SIBO, hepatic enceph | 14-day course, durable effect |
Decision shortcut
- Confirmed mild-to-moderate ulcerative colitis flare: Mesacol 4.8 g daily for induction, then taper to 2.4 g for maintenance. Add corticosteroid course only if flare is severe.
- UC maintenance, simple regimen: Mesacol OD once daily — best adherence equals best long-term remission.
- UC plus rheumatoid arthritis: Salazar or Sazo (sulfasalazine) — dual disease activity in one drug.
- IBS with cramping (any subtype): Colospa 135 mg three times daily before meals.
- IBS-D (predominant diarrhoea): Rifagut 550 mg three times daily for 14 days; effect lasts 6–10 weeks. Repeat course if symptoms recur.
- Suspected SIBO (small intestinal bacterial overgrowth): Rifagut as above; hydrogen-methane breath test confirms.
- Hepatic encephalopathy prophylaxis (cirrhosis): Rifagut 550 mg twice daily long-term.
- Severe or steroid-dependent IBD: requires specialist care — biologics (anti-TNF, vedolizumab, ustekinumab) and immunomodulators (azathioprine, methotrexate) are not stocked at MedsBase.
Frequently asked questions
What’s the difference between IBS and IBD?
IBS (irritable bowel syndrome) is a functional disorder — altered gut motility and visceral hypersensitivity without structural disease. IBD (inflammatory bowel disease) is autoimmune inflammation that damages the bowel wall — Crohn’s disease and ulcerative colitis. They share some symptoms (abdominal pain, altered bowel habit) but require different diagnostic workup and entirely different treatments. IBS responds to antispasmodics, dietary intervention, and gut-directed CBT; IBD requires anti-inflammatory drugs, immunomodulators, or biologics.
How do I know if I have IBS or IBD?
You don’t — and shouldn’t guess. Red flags that mandate IBD workup include rectal bleeding, weight loss, nocturnal symptoms (waking from sleep with pain or diarrhoea), fever, abnormal blood tests (elevated CRP, low haemoglobin), elevated faecal calprotectin (>100–250 µg/g raises strong IBD suspicion), and family history of IBD or bowel cancer. A clinician orders the right tests; colonoscopy with biopsy is the definitive distinction.
Which 5-ASA is best for ulcerative colitis?
For most UC patients, mesalamine (Mesacol or Mesacol OD) has the better tolerability and supports adherence over years. Sulfasalazine (Salazar / Sazo) is preferred when there’s concurrent rheumatoid arthritis or seronegative spondyloarthropathy. The choice between Mesacol and Asacol is about colonic delivery mechanism — pH-dependent vs Eudragit — and largely individual response.
Can I take 5-ASAs for IBS?
No — 5-ASAs treat colonic inflammation that doesn’t exist in IBS. They have no role in IBS treatment and carry their own risks (interstitial nephritis, pancreatitis). Antispasmodics like Colospa, dietary intervention (low-FODMAP), gut-directed CBT, and Rifagut for IBS-D are the IBS-appropriate options.
Is mebeverine the same as buscopan?
Different mechanisms. Mebeverine (Colospa) is musculotropic — acts directly on smooth muscle without antimuscarinic effects. Buscopan (hyoscine butylbromide) is antimuscarinic — blocks acetylcholine at smooth muscle receptors. Mebeverine is preferred for chronic IBS use because it lacks the dry-mouth, blurred-vision, and constipation effects of antimuscarinics. Buscopan is more useful for acute spasm or single-dose pre-procedure use.
What does rifaximin actually do for IBS-D?
Rifaximin reduces bacterial fermentation and gas production in the gut by suppressing the bacterial overgrowth that drives many IBS-D and IBS-bloating symptoms. The TARGET 3 trial showed sustained relief in 36–47% of IBS-D patients beyond 6 weeks after a single 14-day course; about 30% achieved durable response. Repeat courses are effective in patients who initially responded.
Why are biologics not stocked here?
Biologics (infliximab, adalimumab, vedolizumab, ustekinumab) are large protein molecules requiring cold-chain handling, IV or subcutaneous administration, specialist titration based on disease activity and drug levels, and direct hospital-pharmacy supply chains. They are not appropriate for self-managed online ordering. Patients with moderate-severe IBD that needs biologics require specialist gastroenterology care.
Are sulfasalazine side effects worth the cost saving?
For most patients on long-term IBD maintenance, mesalamine’s better tolerability outweighs sulfasalazine’s lower price. Sulfasalazine’s male infertility (reversible) and folate-deficiency requirements are real considerations. Where sulfasalazine wins is in patients with both IBD and rheumatoid arthritis — single drug, dual disease activity — and in cost-constrained settings where mesalamine isn’t accessible.
Bottom line
Get the diagnosis right first — IBS and IBD need different drugs. For confirmed mild-to-moderate UC, Mesacol or Mesacol OD is the foundation, sulfasalazine the alternative when RA co-exists. For IBS, mebeverine handles cramping and rifaximin handles diarrhoea-predominant subtype. Severe IBD, steroid-dependent disease, or perianal Crohn’s requires specialist care beyond what these oral generics can provide.
Related guides: All IBS & IBD products · Best antibiotics 2026 · Gastro health category
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.